The Extraordinary Shareholders Meeting of Solvac held on 17 November 2015 authorised the Board of Directors to increase the company's share capital in order to enable it to fully subscribe, for an amount of around EUR 450 million to the share capital increase announced by Solvay to finance in part the acquisition of Cytec.
In addition to the already existing authorisation of EUR 45 million (exclusive of share premium), the shareholders granted a new specific authorisation for a maximum sum of EUR 65 million (exclusive of share premium).
This authorisation, which remains valid up to 31 December 2016, will enable the Board of Directors to increase the company's share capital with all the flexibility needed, it being understood that the increase will be with legal or extra-legal preference right given to existing shareholders.
A capital increase on around EUR 450 million is equivalent to approximately 25% of the stock market capitalisation of Solvac.
Shareholders are as of now invited to look at the Q&A relating to the process of Solvac's capital increase, which appears on the home page of Solvac website (www.solvac.be)
Details of the results of the vote are also available on Solvac website (www.solvac.be/assemblees-generales).
For more information, please contact:
SOLVAC S.A.
Investor Relations
Rue des Champs Elysées, 43 - 1050 Brussels
Tel.: 32/2/639.66.30
Fax: 32/2/639 66 31
Mail: Investor.relations@solvac.be
Dit persbericht is ook in het Nederlands beschikbaar - Ce communiqué de presse est également disponible en français
